Category: Diabetes

Supertrialistas: ¿una nueva modalidad olímpica? – @nogracias_eu

“Marc Casañas y Jorge Ramírez son dos voces críticas necesarias; Marc, estudiante avezado de nutrición, además de ser un incesante generador de noticias en su twiter, ya ha colaborado con nosotros con una estupenda crónica de la Jornada “Pastillas las justas” y ha realizado varias traducciones (como esta de un texto del BMJ sobre la…

Hello AstraZeneca: #Onglyza Database

Ramirez, Jorge H (2015): ClinicalTrials.gov – 101 studies found for: saxagliptin (search date: April 12, 2015). figshare. http://dx.doi.org/10.6084/m9.figshare.1375296 HT PharmaGossip: “Pulls”! Really? FDA Pulls Diabetes Drug Onglyza Citing Increased Risk Of Death | Multisource Video News Analysis http://t.co/kbeRKktVE6? — pharmagossip (@pharmagossip) abril 11, 2015 #astrazeneca #Onglyza . What the #FDA is saying: http://t.co/iatyEsglr3 — pharmagossip…

Response to @GSK: “It is easier to put a man on the moon than develop a #malaria vaccine. For starters, you can see the moon.” ―Andrew Witty

"It is easier to put a man on the moon than develop a #malaria vaccine. For starters, you can see the moon." Andrew Witty #BSR14 — GSK (@GSK) November 4, 2014 Hey Andrew! Just put an extra spoon of green sugar, available in a shynny pharmaceutical form, papers with a weird symbol printed somewhere, green…

About the safety and effectiveness of incretins (gliptins) in type 2 diabetic patients

  1. Towards better patient care: drugs to avoid in 2014 ―Prescrire International English – Medicamentos peligrosos (By Prescrire): analysis by Plataforma NoGracias.       – Boletin Med-Informatica, Federación Médica Colombiana. PRESCRIRE Internacional Incluye Sitagliptina, Saxagliptina y Linagliptina en Lista Negativa de Medicamentos Inservibles (2014). 2. BMJ Open Data Campaign: Incretin Mimetics “Incretin therapies—glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4…

Incretin mimetics: liraglutide (Victoza) unpublished studies (ClinicalTrials.gov, EudraCT, and UMIN) → 69%

  Background: “Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage” – Re: let’s start this discussion again Unpublished & published liraglutide studies in humans – Completed before Jan 1, 2011 – – Unpublished (n=37): 68.5% – Published (n=17): 31.5% → 3.1 papers per published study record. 90% of the studies (35 / 39) were retrospectively registered Median (Interquartile range: Q1…